From our Annual Public Meeting to topic-specific convenings, the Reagan-Udall Foundation for the FDA brings stakeholders together on matters critical to regulatory science and practice. These events, often hosted at the request of FDA leadership, provide space for expert analysis and candid discussion on FDA’s priority issues. See below for upcoming events.

Past Events

UPDATED: Aetion pushes Series B to $82M as pandemic puts real-world evidence under the spotlight - Endpoints News
Former FDA chief Scott Gottlieb’s favorite real-world evidence platform is getting a new stream of cash, as it nears what will likely be the biggest test of the young company so far.
FDA In Brief: Findings from Real-World Data Study Reveal Higher Risk of Hospitalization and Death Among Cancer Patients with COVID-19, Underscore Health Disparities
The following quote is attributed to Harpreet Singh, M.D., Associate Director, Cancer in Older Adults and Special Populations, FDA’s Oncology Center of Excellence; and Director, Division of Oncology 2, FDA’s Center for Dru
FDA’s Ongoing Work to Support and Advance COVID-19 Diagnostic Test Accuracy and Availability
The U. S.
Industry Voices—How real-world EHR data are enhancing our understanding of COVID-19 - Fierce Healthcare
Traditionally, the healthcare industry has moved slowly when embracing new technology innovations.
FDA to Participate in Covid-19 Diagnostics Evidence Accelerator - Bloomberg Law
The FDA will participate in the Covid-19 Diagnostics Evidence Accelerator, a multi-stakeholder collaborative project organized by the Reagan-Udall Foundation for the FDA in collaboration with Frien
HAHN PLEDGES TO EVALUATE FUTURE OF DIAGNOSTICS REGULATION - POLITICO Prescription Pulse
At a Medical Device Innovation Consortium fireside chat Thursday, FDA Commissioner Stephen Hahn said the agency will take a fresh look at how it regulates diagnostics and digital technologies after the coronavirus pandemic
Pandemic pushes FDA to 'accelerate' real-world evidence efforts, Hahn says - MedTech Dive
FDA is upping efforts to incorporate real-world data in evaluation of COVID-19 diagnostics and antibody tests, 
FDA joins Reagan-Udall, Friends of Cancer Research to form COVID-19 Diagnostics Evidence Accelerator - The Cancer Letter
FDA is participating in the COVID-19 Diagnostics Evidence Accelerator, a multi-stakeholder collaborative project to advance the development of diagnostics.  The accelerator is organized by the Reagan-Udall Founda
Accelerating the fight against COVID-19 with real-world data on tests - BioCentury
Almost every aspect of the fight against COVID-19 depends on the ability to determine whether an individual is or has been infected with SARS-CoV-2, but more than six months into the pandemic there is still uncertainty abo
To expedite progress against COVID-19, a public-private “accelerator” taps into real-world data - The Cancer Letter
This story is part of The Cancer Letter’s ongoing coverage of COVID-19’s impact on oncology.